ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NVUS Novus Therapeutics Inc

14.60
0.00 (0.00%)
07 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novus Therapeutics Inc NASDAQ:NVUS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.60 14.65 21.00 0 01:00:00

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Tokai Pharmaceuticals, Inc. of a Class Action Lawsuit & a L...

19/09/2016 6:33pm

Business Wire


Novus Therapeutics (NASDAQ:NVUS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Novus Therapeutics Charts.

The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Tokai Pharmaceuticals, Inc. (NASDAQGM: TKAI) between June 24, 2015 through July 25, 2016.

You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired Tokai securities between June 24, 2015 and July 25, 2016, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/tokai-pharmaceuticals-tkai

The complaint alleges that throughout the Class Period, Defendants issued false and/or misleading statements to investors and/or failed to disclose that: (1) there were noteworthy structural problems with ARMOR3-SV, the trial design for Tokai's pivotal Phase 3 Galeterone study, (2) accordingly, ARMOR3-SV would probably not meet its primary endpoint; (3) therefore, the likelihood of Galeterone's commercialization was not as probable as Tokai had told investors; and (4) consequently, Tokai's financial statements were false and misleading and/or lacked a reasonable basis.

Additionally, on July 26, 2016, Tokai announced it would end a late-stage trial of Galeterone, saying it believed the stage 3 study would not meet its primary endpoint. Following this news, Tokai shares fell from $5.20 on July 25, 2016, to a close of $1.10 on July 26, 2016.

If you suffered a loss in Tokai, you have until September 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/tokai-pharmaceuticals-tkai

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLPEduard Korsinsky, Esq.Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171www.zlk.com

1 Year Novus Therapeutics Chart

1 Year Novus Therapeutics Chart

1 Month Novus Therapeutics Chart

1 Month Novus Therapeutics Chart

Your Recent History

Delayed Upgrade Clock